Jun 30, 2024

Ekso Bionics Q2 2024 Earnings Report

Ekso Bionics reported record quarterly sales in Q2 2024.

Key Takeaways

Ekso Bionics reported record revenues of $5.0 million for the second quarter of 2024, a 5% increase compared to the same period in 2023. The company achieved a gross margin of 53% and sold 37 EksoHealth devices.

Reported revenues of $5.0 million in the second quarter of 2024.

Initial Medicare claims for Ekso Indego Personal are currently pending reimbursement.

Sold a total of 37 EksoHealth devices in the second quarter of 2024.

Achieved gross margin of 53% for the quarter ended June 30, 2024.

Total Revenue
$4.95M
Previous year: $4.7M
+5.3%
EPS
-$0.13
Previous year: -$0.31
-58.1%
Gross Profit
$2.6M
Previous year: $2.25M
+15.4%
Cash and Equivalents
$5.9M
Previous year: $13.3M
-55.7%
Free Cash Flow
-$2.67M
Previous year: -$2.96M
-9.7%
Total Assets
$38.9M
Previous year: $34M
+14.5%

Ekso Bionics

Ekso Bionics

Forward Guidance

The company is focused on reaching a larger U.S. population of individuals living with a spinal cord injury and anticipate increased demand for Ekso Indego Personal in the second half of the year and longer term. They will continue to execute upon their scalable commercial strategy to drive growth while bringing transformational benefits to patients across the continuum of care.